Jounce Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Jounce Therapeutics, Inc.‘s stocks are currently a part of 108 hedge funds’ portfolios, which represents 83.17% of the total amount of its stocks outstanding. This makes up a total of 41.52M shares of Jounce Therapeutics, Inc.. Compared to the previous quarter, the number grew by 2.85% or 1.14M shares more. As for the holding position changes, 30.56% (33) of current hedge fund investors increased the number of shares held, 37.04% (40) of current holders sold a part of the shares held, and 18.52% (20) closed the holdings completely. 9 hedge funds are new holders of Jounce Therapeutics, Inc. stock in Q1 2022, it is 8.33% of total holders.
Hedge funds holding Jounce Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 71 |
|---|---|
| Q3 2017 | 74 |
| Q4 2017 | 82 |
| Q1 2018 | 94 |
| Q2 2018 | 82 |
| Q3 2018 | 84 |
| Q4 2018 | 81 |
| Q1 2019 | 78 |
| Q2 2019 | 78 |
| Q3 2019 | 75 |
| Q4 2019 | 96 |
| Q1 2020 | 84 |
| Q2 2020 | 87 |
| Q3 2020 | 98 |
| Q4 2020 | 99 |
| Q1 2021 | 117 |
| Q2 2021 | 126 |
| Q3 2021 | 111 |
| Q4 2021 | 120 |
| Q1 2022 | 108 |
Hedge funds changes in Jounce Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 21 | 27 | 16 | 9 | -2 |
|---|---|---|---|---|---|
| Q3 2017 | 12 | 37 | 10 | 9 | 6 |
| Q4 2017 | 18 | 36 | 16 | 10 | 2 |
| Q1 2018 | 26 | 26 | 29 | 13 | 0 |
| Q2 2018 | 19 | 28 | 22 | 31 | -18 |
| Q3 2018 | 16 | 28 | 19 | 14 | 7 |
| Q4 2018 | 15 | 31 | 20 | 17 | -2 |
| Q1 2019 | 9 | 24 | 30 | 12 | 3 |
| Q2 2019 | 7 | 26 | 30 | 5 | 10 |
| Q3 2019 | 9 | 28 | 22 | 12 | 4 |
| Q4 2019 | 30 | 28 | 24 | 8 | 6 |
| Q1 2020 | 15 | 36 | 19 | 25 | -11 |
| Q2 2020 | 12 | 28 | 31 | 9 | 7 |
| Q3 2020 | 23 | 20 | 39 | 12 | 4 |
| Q4 2020 | 15 | 25 | 41 | 14 | 4 |
| Q1 2021 | 38 | 31 | 31 | 20 | -3 |
| Q2 2021 | 22 | 62 | 24 | 13 | 5 |
| Q3 2021 | 11 | 43 | 34 | 25 | -2 |
| Q4 2021 | 22 | 36 | 35 | 13 | 14 |
| Q1 2022 | 9 | 33 | 40 | 20 | 6 |
Hedge funds changes in Jounce Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 0 | 173,000 |
| Q1 2018 | 21,373,000 | 1,582,000 |
| Q2 2018 | 2,101,000 | 1,151,000 |
| Q3 2018 | 3,944,000 | 543,000 |
| Q4 2018 | 18,000 | 0 |
| Q1 2019 | 171,000 | 0 |
| Q2 2019 | 161,000 | 58,000 |
| Q3 2019 | 57,000 | 0 |
| Q4 2019 | 876,000 | 839,000 |
| Q1 2020 | 448,000 | 216,000 |
| Q2 2020 | 639,000 | 128,000 |
| Q3 2020 | 1,722,000 | 1,543,000 |
| Q4 2020 | 1,064,000 | 1,444,000 |
| Q1 2021 | 596,000 | 3,221,000 |
| Q2 2021 | 340,000 | 1,726,000 |
| Q3 2021 | 570,000 | 180,000 |
| Q4 2021 | 396,000 | 1,000 |
| Q1 2022 | 390,000 | 410,000 |